Given the early involvement of autophagy dysfunction in AD pathogenesis, autophagy-related molecules (e.g., LC3, p62, and LAMP-2A) emerge as promising preclinical biomarkers that could facilitate earlier diagnosis and intervention. Here, MAP1LC3A is linked to Alzheimer disease.